What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2026-09-09 compared with 2026-06-10 · 144 added, 143 removed, 546 unchanged (34% of the section changed)

4 unchanged sentences

thousands, except share and per share data)

April 30, 2026

October 31, 2025

Current assets:

8 unchanged sentences

Accrued expenses

Operating lease liability

Operating lease liability, current

Total current liabilities

9 unchanged sentences

no shares issued or outstanding

Preferred stock, value

Common stock, par value $ .01 per share;

100,000,000 shares authorized;

33,922,776 and 33,013,829 shares issued and outstanding as of April 30, 2026 and October 31, 2025, respectively

34,584,538 and 33,013,829 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively

Additional paid-in capital

9 unchanged sentences

For the three months ended

For the six months ended

For the nine months ended

Operating expenses:

15 unchanged sentences

thousands, except share data)

THE THREE MONTHS ENDED APRIL 30, 2026 (UNAUDITED )

THE THREE MONTHS ENDED JULY 31, 2026 (UNAUDITED )

Shareholders’

Balance, January 31, 2026

Balance, April 30, 2026

$ ( 256,758 ) -

2 unchanged sentences

Common stock issued in an at-the-market offering, net of offering expenses of $ 72

Common stock issued pursuant to an employee stock purchase plan

Cancelation of treasury shares

Common stock issued upon exercise of stock options

Balance, April 30, 2026

Balance, July 31, 2026

$ ( 259,364 ) -

THE THREE MONTHS ENDED APRIL 30, 2025 (UNAUDITED )

THE THREE MONTHS ENDED JULY 31, 2025 (UNAUDITED )

Shareholders’

Balance, January 31, 2025

Balance, April 30, 2025

$ ( 246,724 ) -

2 unchanged sentences

Common stock issued in an at-the-market offering, net of offering expenses of $ 73

Common stock issued pursuant to an employee stock purchase plan

Cancelation of treasury shares

Balance, April 30, 2025

Common stock issued upon exercise of stock options

Balance, July 31, 2025

$ ( 248,982 ) -

4 unchanged sentences

thousands, except share data)

THE SIX MONTHS ENDED APRIL 30, 2026 (UNAUDITED )

THE NINE MONTHS ENDED JULY 31, 2026 (UNAUDITED )

Shareholders’

6 unchanged sentences

Common stock issued upon exercise of stock options

Balance, April 30, 2026

Balance, July 31, 2026

$ ( 259,364 ) -

THE SIX MONTHS ENDED APRIL 30, 2025 (UNAUDITED)

THE NINE MONTHS ENDED JULY 31, 2025 (UNAUDITED)

Shareholders’

1 unchanged sentence

$ ( 240,750 )

Stock option compensation to employees and directors

1 unchanged sentence

Common stock issued in an at-the-market offering, net of offering expenses of $ 123

Common stock issued in an at-the-market offering, net of offering expenses

Common stock issued in an

at-the-market offering, net of offering expenses

Common stock issued upon exercise of stock options

Common stock issued pursuant to an employee stock purchase plan

Cancelation of treasury shares

Balance, April 30, 2025

Balance, July 31, 2025

$ ( 248,982 )

accompanying notes are an integral part of these condensed consolidated financial statements.

2 unchanged sentences

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

For the six months ended

For the nine months ended

Cash flows from operating activities:

3 unchanged sentences

Amortization of operating lease right-of-use asset

Amortization of discount on held-to-maturity securities

Change in amortization of discount on held-to-maturity securities

Change in operating assets and liabilities:

9 unchanged sentences

Cash flows from financing activities:

Proceeds (expenses) from sale of common stock in an at-the-market offering, net of offering expenses of $ 135 and $ 51 , respectively

Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $ 207 and $ 123 , respectively

Proceeds from sale of common stock pursuant to an employee stock purchase plan

15 unchanged sentences

cell therapy, which is a novel form of chimeric antigen receptor-T cell (“CAR-T”) technology, initially focused on treating

ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc.

ovarian cancer, that is being developed by our subsidiary, Certainty Therapeutics, Inc.

(“Certainty”).

15 unchanged sentences

activities by the Company.

Due to such Company funding, Wistar’s equity stake in Certainty was 3.9 % as of April 30, 2026.

Due to such Company funding, Wistar’s equity stake in Certainty was 3.8 % as of July 31, 2026.

in collaboration with the H.

Lee Moffitt Cancer Center and Research Institute, Inc.

(“Moffitt”), has begun human clinical

testing of lira-cel, the CAR-T technology licensed by Certainty from Wistar aimed at treating ovarian cancer.

After receiving authorization

from the U.S.

Food and Drug Administration (“FDA”), we commenced enrollment of patients in a Phase 1 clinical trial and treated

the first patient in August 2022.

Further, in May 2023 and August 2023, we treated the second and third patients in the trial, respectively,

at the same dose level as the first patient, and the treatment was well-tolerated by the patients.

Between February and June 2024, we

treated the three patients of the second dose cohort, where the patients were administered a three-times higher dose of cells than the

patients in the first cohort.

The treatment at this dose level was also well-tolerated by the patients.

From November 2024 to February

2025, we treated three patients in the third dose cohort, where they were administered a ten-times higher dose of cells than the patients

in the first dose cohort.

Consistent with the lower dose cohorts, the treatment was well-tolerated by the patients.

Subsequently, we

have treated patients in the fourth dose cohort, administering a 30-times higher dose of cells than the patients in the first dose cohort,

and again the treatment appears to have been well-tolerated.

the dose levels in these cohorts were expected to be sub-therapeutic, multiple patients have exhibited anecdotal signs of efficacy, including

possible signs of T cell infiltration, tumor necrosis and encouraging survival observations.

Through the date of this Report, thirteen

patients have been treated, and several have lived significantly beyond their expected median survival of approximately three to four

months, based on disease stage and prior therapy history.

One patient survived 28 months following treatment, four patients have survived

one year or more following treatment, at 19, 18, 17 and 12 months, respectively, and four additional patients have survived 11, 8 and

7 months, respectively.

The three patients that have reached 19, 18 and 12 months, respectively, remain alive, and one additional patient

who was treated more recently, is also currently alive.

While the study is designed to primarily demonstrate safety,

we believe this pattern of extended survival represents encouraging, albeit anecdotal, evidence of clinical activity in a patient population

with limited therapeutic options.

(“Moffitt”), has begun human

clinical testing of lira-cel, the CAR-T technology licensed by Certainty from Wistar aimed at treating ovarian cancer.

receiving authorization from the U.S.

Food and Drug Administration (“FDA”), we commenced enrollment of patients in a

Phase 1 clinical trial and treated the first patient in August 2022.

Further, in May 2023 and August 2023, we treated the second and

third patients in the trial, respectively, at the same dose level as the first patient, and the treatment was well-tolerated by the

Between February and June 2024, we treated the three patients of the second dose cohort, where the patients were

administered a three-times higher dose of cells than the patients in the first cohort.

The treatment at this dose level was also

well-tolerated by the patients.

From November 2024 to February 2025, we treated three patients in the third dose cohort, where they

were administered a ten-times higher dose of cells than the patients in the first dose cohort.

Consistent with the lower dose

cohorts, the treatment was well-tolerated by the patients.

Subsequently, we treated four patients in the fourth dose cohort,

administering a 30-times higher dose of cells than the patients in the first dose cohort, and again the treatment appears to have

been well-tolerated.

In June 2026, we treated the first patient in the next higher dose cohort.

Following lymphodepletion, this

patient received a 100-times higher dose of cells than the patients in the first dose cohort, and consistent with other trial

participants, the treatment appeared to be safe and well-tolerated.

in this trial are highly pre-treated, recurrent and resistant ovarian cancer patients, who have failed conventional therapies and are

While the results are preliminary and in a small number of subjects, multiple patients have exhibited anecdotal signs of

efficacy, including possible signs of T cell infiltration, tumor necrosis and encouraging survival observations.

In addition, through

the date of this Report, fourteen patients have been treated, and four have surpassed one year of survival following treatment, with

the longest having survived 28 months.

While the study is designed to primarily demonstrate safety, we believe this pattern of extended

survival represents encouraging, albeit anecdotal, evidence of clinical activity in a patient population with limited therapeutic options.

study is a dose-escalation trial with two arms based on route of delivery—intraperitoneal or intravenous—to determine the

74 unchanged sentences

Working with Cleveland Clinic researchers, we are focusing on the same novel scientific mechanism as in our breast and ovarian

cancer vaccines, and working to discover additional retired proteins that may be associated with other forms of cancer, specifically

high incidence malignancies in the lung, colon and prostate.

cancer vaccines and working to discover additional retired proteins that may be associated with other forms of cancer, specifically high

incidence malignancies in the lung, colon and prostate.

the next several quarters, we expect the development of our therapeutics and vaccines to be the primary focus of the Company.

of our legacy operations, the Company remains engaged in limited patent licensing activities of its various patent portfolios.

not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require

material financial resources or attention of senior management.

not expect these activities to be a significant part of the Company’s ongoing operations, nor do we expect these activities to

require material financial resources or attention of senior management.

the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from

10 unchanged sentences

and Management’s Plans

on currently available information as of June 10, 2026, we believe that our existing cash, cash equivalents and short-term investments

on currently available information as of September 9, 2026, we believe that our existing cash, cash equivalents and short-term investments

will be sufficient to fund our activities for at least the next twelve months.

The Company had approximately $ 13,864,000 of cash, cash

equivalents and short-term investments at April 30, 2026 compared to approximately $ 15,174,000 at October 31, 2025 which is a reduction

of approximately $ 1,488,000 for the six months ended April 30, 2026.

equivalents and short-term investments at July 31, 2026 compared to approximately $ 15,174,000 at October 31, 2025 which is a reduction

of approximately $ 1,310,000 for the nine months ended July 31, 2026.

Therefore, the Company believes that it has sufficient cash, cash

3 unchanged sentences

technologies.

During the six months ended April 30, 2026, we raised approximately $ 2,870,000 , net of expenses, through an at-the-market

During the nine months ended July 31, 2026, we raised approximately $ 4,806,000 , net of expenses, through an at-the-market

equity offering of 1,548,324 shares of common stock.

Under our at-the-market equity program, which is currently effective and may remain

available for us to use in the future, as of April 30, 2026, we may sell approximately $ 97 million of common stock.

available for us to use in the future, as of July 31, 2026, we may sell approximately $ 95 million of common stock.

SIGNIFICANT ACCOUNTING POLICIES

10 unchanged sentences

The condensed consolidated financial statements include all adjustments of

a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of April

a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of July

31, 2026, and results of operations and cash flows for the interim periods represented.

The results of operations for the three and six

months ended April 30, 2026 are not necessarily indicative of the results to be expected for the year.

The results of operations for the three and nine

months ended July 31, 2026 are not necessarily indicative of the results to be expected for the year.

Noncontrolling

2 unchanged sentences

The following table sets

forth the changes in noncontrolling interest for the six months ended April 30, 2026 (in thousands):

forth the changes in noncontrolling interest for the nine months ended July 31, 2026 (in thousands):

SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST

1 unchanged sentence

Net loss attributable to noncontrolling interest

Balance, April 30, 2026

Balance, July 31, 2026

revenue has been derived solely from technology licensing and the sale of patented technologies.

25 unchanged sentences

These costs are

included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.

included under the caption “Operating expenses” in the accompanying condensed consolidated statements of operations.

and Development Expenses

34 unchanged sentences

We recorded stock-based compensation expense related to service-based

stock options granted to employees and directors of approximately $ 637,000 and $ 962,000 during the three months ended April 30, 2026

and 2025, respectively, and approximately $ 1,405,000 and $ 1,993,000 during the six months ended April 30, 2026 and 2025, respectively.

stock options granted to employees and directors of approximately $ 637,000 and $ 829,000 during the three months ended July 31, 2026 and

2025, respectively, and approximately $ 2,042,000 and $ 2,822,000 during the nine months ended July 31, 2026 and 2025, respectively.

compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the

award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting

period of the stock option) which is one to three years.

We recorded stock-based consulting expense related to stock options granted

to consultants of approximately $ 28,000 and $ 26,000 during the three months ended April 30, 2026 and 2025, respectively, and approximately

$ 56,000 , and $ 50,000 , during the six months ended April 30, 2026 and 2025, respectively.

period of the stock option) which is generally one to three years.

We recorded stock-based consulting expense related to stock options

granted to consultants of approximately $ 29,000 and $ 26,000 during the three months ended July 31, 2026 and 2025, respectively, and approximately

$ 85,000 , and $ 77,000 , during the nine months ended July 31, 2026 and 2025, respectively.

Option Activity

the three months ended April 30, 2026 and 2025, we did no t grant any options to purchase shares of common stock, and during the six months

ended April 30, 2026 and 2025, we granted options to purchase 720,000 shares and 1,355,000 shares of common stock, respectively, to employees

and consultants, with exercise prices ranging from $ 3.18 to $ 3.24 per share, pursuant to the Anixa Biosciences, Inc.

2018 Share Incentive

Plan (the “2018 Share Plan”).

During the three months ended April 30, 2026, no stock options were exercised.

During the six

months ended April 30, 2026, stock options to purchase 20,283 shares of common stock were exercised on a cash basis, with aggregate proceeds

of approximately $ 60,000 .

During the three and six months ended April 30, 2025, no stock options were exercised.

the three and six months ended April 30, 2026, we had two stock option plans:

the three months ended July 31, 2026 and 2025, we granted options to purchase 0 shares and 75,000 shares of common stock, respectively,

and during the nine months ended July 31, 2026 and 2025, we granted options to purchase 720,000 shares and 1,430,000 shares of common

stock, respectively, to employees and consultants, with exercise prices ranging from $ 3.18 to $ 3.24 per share, pursuant to the Anixa

Biosciences, Inc.

2018 Share Incentive Plan (the “2018 Share Plan”).

the three months ended July 31, 2026, stock options to purchase 6,000 shares of common stock, of which 5,428 shares of common stock were

withheld to cover the exercise price, were exercised on a cashless basis.

During the nine months ended July 31, 2026, stock options to

purchase 20,283 shares of common stock were exercised on a cash basis, with aggregate proceeds of approximately $ 60,000 and 6,000 shares

of common stock were exercised on a cashless basis of which 5,428 shares of common stock were withheld to cover the exercise price.

the three and nine months ended July 31, 2025, stock options to purchase 685 shares of common stock were exercised on a cash basis, with

aggregate proceeds of approximately $ 2,000 and 35,000 shares of common stock were exercised on a cashless basis of which 21,642 shares

of common stock were withheld to cover the exercise price.

the three and nine months ended July 31, 2026, we had two stock option plans:

the Anixa Biosciences, Inc.

7 unchanged sentences

respect to the ability to grant future awards on July 14, 2020.

Information regarding the 2010 Share Plan for the six months ended April

Information regarding the 2010 Share Plan for the nine months ended July

31, 2026 is as follows:

6 unchanged sentences

Forfeited/expired

Options outstanding and exercisable at April 30, 2026

following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2026:

Options outstanding and exercisable at July 31, 2026

The following table summarizes

information about stock options outstanding and exercisable under the 2010 Share Plan as of July 31, 2026:

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE

1 unchanged sentence

Outstanding and

Weighted Average

Contractual Life

Exercise Price

$ 0.67 - $ 0.96

$ 2.27 - $ 3.46

$ 4.85 - $ 5.30

2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards,

performance awards and stock units to employees, directors and consultants.

As of April 30, 2026, the 2018 Share Plan had 1,395,000 shares

As of July 31, 2026, the 2018 Share Plan had 1,395,000 shares

available for future grants.

Information regarding the 2018 Share Plan for the six months ended April 30, 2026 is as follows:

Information regarding the 2018 Share Plan for the nine months ended July 31, 2026 is as follows:

SCHEDULE OF OPTION ACTIVITY

5 unchanged sentences

Forfeited/expired

Options outstanding at April 30, 2026

Options exercisable at April 30, 2026

following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2026:

Options outstanding at July 31, 2026

Options exercisable at July 31, 2026

following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of July 31, 2026:

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE

8 unchanged sentences

$ 3.17 - $ 3.87

$ 4.02 - $ 5.04

Stock Purchase Plan

5 unchanged sentences

by our shareholders on September 27, 2018.

During the six months ended April 30, 2026 and 2025, employees purchased 1,530 shares and

During the nine months ended July 31, 2026 and 2025, employees purchased 1,530 shares and

1,518 shares, respectively, under the ESPP with aggregate proceeds of approximately $ 4,000 and $ 4,000 , respectively.

of April 30, 2026, we had no warrants

Information regarding the Company’s warrant activity for the six months ended April 30, 2026 is as

of July 31, 2026, we had no warrants outstanding.

Information regarding the Company’s warrant activity for the nine months ended

July 31, 2026 is as follows:

SCHEDULE OF WARRANTS ACTIVITY

1 unchanged sentence

Warrants outstanding at October 31, 2025

Warrants outstanding and exercisable at April 30, 2026

the three and six months ended April 30, 2026 and 2025, we did not issue any stock awards.

of April 30, 2026 and 2025, the Company held no shares as treasury stock.

During the fiscal year ended October 31, 2024, the Company

purchased 2,000 shares of its common stock at an average cost of $ 3.17 per share for a total cost of approximately $ 6,000 .

These treasury

shares were subsequently canceled in March 2025.

The repurchases were made as part of a stock buyback program approved by our Board of

Directors on July 11, 2024.

Warrants outstanding and exercisable at July 31, 2026

the three and nine months ended July 31, 2026 and 2025, we did not issue any stock awards.

of July 31, 2026 and 2025, the Company held no shares as treasury stock.

During the fiscal year ended October 31, 2024, the Company purchased

2,000 shares of its common stock at an average cost of $ 3.17 per share for a total cost of approximately $ 6,000 .

These treasury shares

were subsequently canceled in March 2025.

The repurchases were made as part of a stock buyback program approved by our Board of Directors

on July 11, 2024.

The stock buyback program expired on its 12-month anniversary.

The treasury shares were accounted for under

the cost method and were recorded as a reduction in shareholders’ equity in the condensed consolidated balance sheet.

The treasury shares were accounted for under the cost

method and were recorded as a reduction in shareholders’ equity in the condensed consolidated balance sheet.

FAIR VALUE MEASUREMENTS

15 unchanged sentences

a market participant would use in pricing the instrument.

following table presents the hierarchy for our financial assets measured at fair value as of April 30, 2026 (in

following table presents the hierarchy for our financial assets measured at fair value as of July 31, 2026 (in thousands):

SCHEDULE OF FINANCIAL ASSETS MEASURED AT FAIR VALUE ON A RECURRING BASIS

6 unchanged sentences

Total financial assets

following table presents the hierarchy for our financial assets measured at fair value as of October 31, 2025 (in

following table presents the hierarchy for our financial assets measured at fair value as of October 31, 2025 (in thousands):

Money market funds:

27 unchanged sentences

is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive.

reason, excluded from the calculation of Diluted EPS for the six months ended April 30, 2026 and 2025, were stock options to purchase

13,772,094 shares and 13,488,062 shares, respectively, and warrants to purchase 0 shares and 300,000 shares, respectively.

reason, excluded from the calculation of Diluted EPS for the three and nine months ended July 31, 2026 and 2025, were stock options to

purchase 13,754,094 shares and 13,462,377 shares, respectively, and warrants to purchase 0 shares and 300,000 shares, respectively.

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In November 2023, the FASB issued

Accounting Standards Update 2023-07, Segment Reporting (Topic 280):

Improvements to Reportable Segment Disclosures, to provide more disaggregated

expense information about a public entity’s reportable segments.

The amendments in this update should be applied retrospectively

and are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024.

of this standard did not have a material impact on our consolidated financial statements and related disclosures (Note 11).

December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740):

24 unchanged sentences

could be subject to limitations under Internal Revenue Code section 382, the effects of which have not been determined by the Company.

We have no unrecognized income tax benefits as of April 30, 2026 and October 31, 2025 and we account for interest and penalties related

We have no unrecognized income tax benefits as of July 31, 2026 and October 31, 2025 and we account for interest and penalties related

to income tax matters, if any, in general and administrative expenses.

7 unchanged sentences

Rent expense was approximately $ 16,000 and $ 16,000 , respectively, for

the three months ended April 30, 2026 and 2025, and approximately $ 31,000 and $ 31,000 , respectively, for the six months ended April 30,

the three months ended July 31, 2026 and 2025, and approximately $ 47,000 and $ 47,000 , respectively, for the nine months ended July 31,

2026 and 2025.

1 unchanged sentence

The remaining

41 -month lease term as of April 30, 2026 for the Company’s lease includes the noncancelable period of the lease and the additional

38 -month lease term as of July 31, 2026 for the Company’s lease includes the noncancelable period of the lease and the additional

two-year option period that the Company is reasonably certain to exercise.

1 unchanged sentence

of impairment are present.

of April 30, 2026, the annual minimum future lease payments of our operating lease liability were as follows (in thousands):

of July 31, 2026, the annual minimum future lease payments of our operating lease liability were as follows (in thousands):

SCHEDULE OF MINIMUM LEASE PAYMENTS

4 unchanged sentences

Present value of future minimum lease payments

Balance as of April 30, 2026:

Balance as of July 31, 2026:

Operating lease liability

Operating lease liability, non-current

COMMITMENTS AND CONTINGENCES

COMMITMENTS AND CONTINGENCIES

than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are

1 unchanged sentence

or financial condition.

of April 30, 2026, our commitments under certain technology license agreements related to our therapeutic and vaccine development programs

of July 31, 2026, our commitments under certain technology license agreements related to our therapeutic and vaccine development programs

for the next twelve months were approximately $ 150,000 .

3 unchanged sentences

of new vaccine targets in high incidence malignancies in prostate, lung and colon and (iii) the further development of our CAR-T technology.

As of April 30, 2026, future payments the Company may make under these agreements, dependent upon, among other things, development of

As of July 31, 2026, future payments the Company may make under these agreements, dependent upon, among other things, development of

analytical methods, formulation feasibility studies, stability testing and results of manufacturing processes, may be approximately $ 2.4

2 unchanged sentences

manage our operations in three reportable segments:

(i) Cancer Vaccines, (ii) CAR-T Therapies, and (iii) Other.

(i) Cancer Vaccines, (ii) CAR-T Therapeutics, and (iii) Other.

The Cancer Vaccines segment

1 unchanged sentence

to address many intractable cancers, including high-incidence malignancies in lung, colon, and prostate.

The CAR-T Therapies segment

The CAR-T Therapeutics segment

consists of the development of an ovarian cancer immunotherapy using a novel type of CAR-T, known as chimeric endocrine receptor-T cell

9 unchanged sentences

Segment operating expenses excluding non-cash stock-based compensation is a non-GAAP measure.

following represents selected financial information for our segments for the three and six months ended April 30, 2026 and 2025, and

as of April 30, 2026 and October 31, 2025 (in thousands):

following represents selected financial information for our segments for the three and nine months ended July 31, 2026 and 2025, and

as of July 31, 2026 and October 31, 2025 (in thousands):

SCHEDULE OF SEGMENT INFORMATION

Cancer Vaccines

CAR-T Therapies

Cancer Vaccines

CAR-T Therapies

For the three months ended April 30,

For the three months ended July 31,

Cancer Vaccines

CAR-T Therapies

CAR-T Therapeutics

Cancer Vaccines

CAR-T Therapies

CAR-T Therapeutics

Research and development expenses

10 unchanged sentences

CAR-T Therapies

For the six months ended April 30,

For the nine months ended July 31,

Cancer Vaccines

CAR-T Therapies

CAR-T Therapeutics

Cancer Vaccines

CAR-T Therapies

CAR-T Therapeutics

Research and development expenses

9 unchanged sentences

CAR-T Therapeutics

costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing

Operating expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing

the enterprise.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements